Your browser doesn't support javascript.
loading
Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease.
Lee, Ji Yeon; Lee, Jee Young; Ko, Jae-Hoon; Hyun, Miri; Kim, Hyun Ah; Cho, Seongcheol; Lee, Yong Dae; Song, Junghoon; Shin, Seunghwan; Peck, Kyong Ran.
Afiliação
  • Lee JY; Division of Infectious Diseases, Department of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, South Korea.
  • Lee JY; Department of Internal Medicine, Seoul Red Cross Hospital, Seoul, South Korea.
  • Ko JH; Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Hyun M; Division of Infectious Diseases, Department of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, South Korea.
  • Kim HA; Division of Infectious Diseases, Department of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, South Korea.
  • Cho S; Department of Internal Medicine, Seoul Red Cross Hospital, Seoul, South Korea.
  • Lee YD; Department of Internal Medicine, Seoul Red Cross Hospital, Seoul, South Korea.
  • Song J; Department of Internal Medicine, Seoul Red Cross Hospital, Seoul, South Korea.
  • Shin S; Department of Internal Medicine, Seoul Red Cross Hospital, Seoul, South Korea.
  • Peck KR; Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Front Immunol ; 12: 772320, 2021.
Article em En | MEDLINE | ID: mdl-34899724
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 4_TD Problema de saúde: 4_pneumonia Assunto principal: Imunoglobulina G / Anticorpos Neutralizantes / Anticorpos Monoclonais Humanizados / SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Front Immunol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Coréia do Sul
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 4_TD Problema de saúde: 4_pneumonia Assunto principal: Imunoglobulina G / Anticorpos Neutralizantes / Anticorpos Monoclonais Humanizados / SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Front Immunol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Coréia do Sul